Generic Medicine Info
Indications and Dosage
Schizophrenia, Psychoses
Adult: Long-term therapy: Up to 300 mg every 4 wk via deep inj.
Elderly: Dose reduction may be needed.

Psychoses, Schizophrenia
Adult: 1-15 mg daily, up to 50 mg daily.
Elderly: Dose reduction may be needed.
Renal Impairment
Dose reduction may be needed.
Coma; CNS depression; pheochromocytoma; bone marrow suppression. Pregnancy and lactation.
Special Precautions
Hepatic or renal impairment; history of jaundice; CV disease; angle-closure glaucoma; diabetes mellitus; hyperthyroidism; Parkinson's disease; epilepsy, depression, myasthenia gravis; prostatic hypertrophy; severe resp disease; blood dyscrasias. May precipitate coma, affect driving; elderly.
Adverse Reactions
Alter temp regulation; neuroleptic malignant syndrome; CNS effects (extrapyramidal effects); GI disturbances; nasal congestion; antimuscurinic symptoms; CV symptoms, endocrine effects; blood dyscrasias; photosensitization, contact sensitization and rashes; jaundice; corneal and lens opacities; purplish pigmentation of skin, cornea, conjunctiva and retina.
Drug Interactions
ACE inhibitors, α-blockers, amantadine, general anaesthetics, angiotensin-II receptor antagonists, antiarrhythmics, tricyclic antidepressants, anxiolytics and hypnotics, apomorphine, artemether with lumefantrine, barbiturates, bromocriptine, cabergoline, calcium-channel blockers, carbamazepine, cimetidine, ethosuximide, levodopa, lisuride, memantine, methyldopa, metoclopramide, opioid analgesics, oxcarbazepine, pergolide, phenytoin, pramipexole, primidone, ritonavir, ropinirole, sibutramine, sympathomimetics, terfenadine, tetrabenazine, tramadol, valproate.
Potentially Fatal: Encephalothic syndrome with concomitant use of lithium.
Mechanism of Action: Bromperidol has properties similar to those of haloperidol. It is used in the treatment of schizophrenia and other psychoses.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Bromperidol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in